Stay updated on Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial

Sign up to get notified when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T19:43:50.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.0, replacing the previous version 2.15.2.
    Difference
    0.3%
    Check dated 2025-05-22T17:32:32.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T04:26:22.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the introduction of a new study on RGX-314 for treating neovascular age-related macular degeneration (nAMD) and the removal of detailed information about previous anti-VEGF therapies. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.
    Difference
    28%
    Check dated 2025-04-16T14:36:48.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T09:25:03.000Z thumbnail image
  7. Check
    97 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-24T20:46:52.000Z thumbnail image

Stay in the know with updates to Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.